Endevica Bio

‌

Endevica Bio's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. Phase 1 Clinical trials in the US are underway.

Industries

Biotechnology, Clinical Trials

Employees

1-10

Links

Org chart

Russell Potterfield

CEO

Collapse

Daniel Marks

Chief Medical Officer

Jordan Delev

Head Of Research And Development

Gene Gerke

Board Of Directors

Teams

This company has no teams yet

Offices

This company has no offices yet

Similar companies

Amgen

280 followers

Fortrea

13 followers

Pluto Biosciences

1 follower

Biogen

140 followers

Regeneron

130 followers

Bio-Rad Laboratories

30 followers

Curie.Bio

2 followers

Kedrion Biopharma - USA

2 followers

PerkinElmer

12 followers

Puma Biotechnology

2 followers

Click Therapeutics

2 followers

Explore companies